PRP or not PRP: Is the debate surrounding platelets‐based blood‐derived products evolving?
Open Access
- 13 March 2025
- journal article
- Published by Wiley in Knee Surgery, Sports Traumatology, Arthroscopy
- Vol. 33 (5) , 1920-1924
Abstract
The increasing interest in biologic treatments for musculoskeletal disorders has led to the advancement of orthobiologics, particularly in non‐operative care through injectable therapies. However, defining these treatments clearly is crucial for proper clinical application. Orthobiologics include biologic substances that enhance healing, such as cell‐based therapies and blood‐derived products. Among these, platelet‐rich plasma (PRP) is widely used, but its classification remains complex due to variations in preparation methods, platelet concentration, leucocyte content, and activation techniques. Strictly, the term ‘PRP’ refers to plasma enriched in platelets relative to baseline blood levels. Yet, scientific debate persists regarding whether platelet count or enrichment is more significant in clinical outcomes. Additionally, leucocyte‐rich and leucocyte‐poor PRPs offer different therapeutic advantages depending on the target tissue, complicating standardization. Similarly, the presence of red blood cells is generally discouraged, given their association with joint inflammation. Beyond the classical ‘PRP’ formulations, alternative blood‐derived products offer distinct biological effects. A standardized classification system is therefore essential for research and clinical application, emphasizing precise documentation of products' characteristics, including platelet count, activation state and bioactive molecule interactions. Understanding these variables and their impact on patient‐specific conditions will refine orthopaedic regenerative strategies and optimize treatment efficacy.Keywords
This publication has 14 references indexed in Scilit:
- Influence of Platelet Concentration on the Clinical Outcome of Platelet-Rich Plasma Injections in Knee OsteoarthritisThe American Journal of Sports Medicine, 2024
- Platelet‐rich plasma injections for the management of knee osteoarthritis: The ESSKA‐ICRS consensus. Recommendations using the RAND/UCLA appropriateness method for different clinical scenariosKnee Surgery, Sports Traumatology, Arthroscopy, 2024
- The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA‐ORBIT consensus. Part 1—Blood‐derived products (platelet‐rich plasma)Knee Surgery, Sports Traumatology, Arthroscopy, 2024
- Leukocyte-Rich versus Leukocyte-Poor Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Double-Blind Randomized TrialThe American Journal of Sports Medicine, 2022
- Bleeding with iron deposition and vascular remodelling in subchondral cysts: A newly discovered feature unique to haemophilic arthropathyHaemophilia, 2021
- Platelet-rich plasma for the treatment of knee osteoarthritis: an expert opinion and proposal for a novel classification and coding systemExpert Opinion on Biological Therapy, 2020
- An important and overlooked parameter in platelet rich plasma preparation: The mean platelet volumeJournal of Cosmetic Dermatology, 2018
- Platelet-Rich Plasma: The Choice of Activation Method Affects the Release of Bioactive MoleculesBioMed Research International, 2016
- Platelet‐rich plasma intra‐articular injections for cartilage degeneration and osteoarthritis: single‐ versus double‐spinning approachKnee Surgery, Sports Traumatology, Arthroscopy, 2011
- Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part III: Leucocyte activation: A new feature for platelet concentrates?Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2006